Edgestream Partners L.P. Takes $2.31 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Edgestream Partners L.P. bought a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 18,459 shares of the biotechnology company's stock, valued at approximately $2,305,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Innealta Capital LLC bought a new stake in Sarepta Therapeutics during the 2nd quarter valued at approximately $31,000. Nkcfo LLC purchased a new stake in Sarepta Therapeutics in the second quarter worth $43,000. Huntington National Bank raised its holdings in Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 175 shares in the last quarter. Riggs Asset Managment Co. Inc. raised its holdings in Sarepta Therapeutics by 33.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 75 shares in the last quarter. Finally, UMB Bank n.a. lifted its position in Sarepta Therapeutics by 105.9% during the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock valued at $48,000 after buying an additional 197 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

Wall Street Analyst Weigh In

SRPT has been the subject of several research reports. Evercore ISI decreased their price target on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating for the company in a research note on Thursday, November 7th. Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a research note on Monday, October 21st. They set a "buy" rating and a $165.00 target price for the company. HC Wainwright dropped their price target on Sarepta Therapeutics from $80.00 to $75.00 and set a "sell" rating on the stock in a research report on Tuesday. UBS Group raised their price objective on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a "buy" rating in a research report on Tuesday, September 17th. Finally, Raymond James reissued an "outperform" rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a report on Thursday, October 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $175.55.

Sarepta Therapeutics Price Performance

Shares of SRPT stock traded down $1.94 on Tuesday, reaching $126.01. The company's stock had a trading volume of 1,075,007 shares, compared to its average volume of 1,365,510. The company has a market capitalization of $12.04 billion, a price-to-earnings ratio of 100.81 and a beta of 0.77. The stock's fifty day simple moving average is $122.56 and its 200-day simple moving average is $131.44. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 1 year low of $83.97 and a 1 year high of $173.25.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.